An Overview of Antivirals against Monkeypox Virus and Other Orthopoxviruses.
J Med Chem
; 66(7): 4468-4490, 2023 04 13.
Article
in English
| MEDLINE | ID: covidwho-2286038
ABSTRACT
The current monkeypox outbreaks during the COVID-19 pandemic have reignited interest in orthopoxvirus antivirals. Monkeypox belongs to the Orthopoxvirus genus of the Poxviridae family, which also includes the variola virus, vaccinia virus, and cowpox virus. Two orally bioavailable drugs, tecovirimat and brincidofovir, have been approved for treating smallpox infections. Given their human safety profiles and in vivo antiviral efficacy in animal models, both drugs have also been recommended to treat monkeypox infection. To facilitate the development of additional orthopoxvirus antivirals, we summarize the antiviral activity, mechanism of action, and mechanism of resistance of orthopoxvirus antivirals. This perspective covers both direct-acting and host-targeting antivirals with an emphasis on drug candidates showing in vivo antiviral efficacy in animal models. We hope to speed the orthopoxvirus antiviral drug discovery by providing medicinal chemists with insights into prioritizing proper drug targets and hits for further development.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Variola virus
/
Orthopoxvirus
/
Monkeypox
/
COVID-19
Topics:
Vaccines
Limits:
Animals
/
Humans
Language:
English
Journal:
J Med Chem
Journal subject:
Chemistry
Year:
2023
Document Type:
Article
Affiliation country:
Acs.jmedchem.3c00069
Similar
MEDLINE
...
LILACS
LIS